B cell modulation in rheumatology

Current Opinion in Pharmacology

Volumn 7, Issue 4, 2007, Pages 426-433

  Silverman, Gregg J ^a   Khanna, Sahil ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; APRIL PROTEIN; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BAFF RECEPTOR 3; BELIMUMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD79A ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6 ANTIBODY; LPJ 394; LYMPHO STAT B; METHOTREXATE; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; RECEPTOR PROTEIN; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; TACI RECEPTOR; TRU 015; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL LINEAGE; CELL MEMBRANE; CELL SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL MEMBRANE; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; RECEPTORS, ANTIGEN, B-CELL;

EID: 34548098116     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.05.006     Document Type: Review

References (55)

1. Shaw T., Quan J., and Totoritis M.C. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62 Suppl 2 (2003) ii55-ii59
2. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24 (2006) 467-496
3. Silverman G.J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54 (2006) 2356-2367
4. Furie R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am 32 (2006) 149-156 x
5. Felson D.T., LaValley M.P., Baldassare A.R., Block J.A., Caldwell J.R., Cannon G.W., Deal C., Evans S., Fleischmann R., Gendreau R.M., et al. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 42 (1999) 2153-2159
6. Goodyear C.S., Sugiyama F., and Silverman G.J. Temporal and dose-dependent relationships between in vivo B cell receptor-targeted proliferation and deletion-induced by a microbial B cell toxin. J Immunol 176 (2006) 2262-2271
7. Silverman G.J., Goodyear C.S., and Siegel D.L. On the mechanism of staphylococcal protein A immunomodulation. Transfusion 45 (2005) 274-280
8. Goodyear C.S., Corr M., Sugiyama F., Boyle D.L., and Silverman G.J. Cutting edge: bim is required for superantigen-mediated B cell death. J Immunol 178 (2007) 2636-2640
9. Viau M., and Zouali M. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice. Mol Immunol 42 (2005) 849-855
10. Silverman G.J., and Goodyear C.S. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 6 (2006) 465-475
11. Uchida J., Lee Y., Hasegawa M., Liang Y., Bradney A., Oliver J.A., Bowen K., Steeber D.A., Haas K.M., Poe J.C., et al. Mouse CD20 expression and function. Int Immunol 16 (2004) 119-129
12. Cartron G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
13. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., Lin W.Y., Hu Z., Lu Y., Chen Y., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
14. Hamaguchi Y., Uchida J., Cain D.W., Venturi G.M., Poe J.C., Haas K.M., and Tedder T.F. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174 (2005) 4389-4399
15. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., and Tedder T.F. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
16. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., and Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
17. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., Keystone E.C., Loveless J.E., Burmester G.R., Cravets M.W., et al., REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 54 (2006) 2793-2806
18. Emery P., Fleischmann R.M., Filipowicz-Sosnowska A., Schechtman J., Ramos-Remus C., Gomez-Reino J.J., Hessey E.W., Shaw T.M., Li N.F., and Agarwal S. Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 52 Suppl 9 (2005) S709 [abstract]
19. Silverman G.J. Targeting of B cells in SLE: rationale and therapeutic opportunities. Bull NYU Hosp Jt Dis 64 (2006) 51-56
20. Schiffenbauer J., and Simon L.S. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?. Lupus 13 (2004) 398-405
21. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., and Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
22. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., and Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590
23. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., and Moutsopoulos H.M. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
24. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long term follow up and predictors of response. Ann Rheum Dis 2007, April 5 [Epub ahead of print].
25. Pijpe J., van Imhoff G.W., Vissink A., van der Wal J.E., Kluin P.M., Spijkervet F.K., Kallenberg C.G., and Bootsma H. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 64 (2005) 958-960
26. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., Vissink A., Kallenberg C.G., and Bootsma H. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
27. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., Candon S., Le Guern V., Aouba A., Sibilia J., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66 (2007) 351-357
28. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
29. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in 11 patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
30. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., and Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45 (2006) 1432-1436
31. Genovese M.C., Kaine J.L., Kohen M.D., Lowenstein M.B., Giudice J.D., Baldassare A.R., Schechtman J., Gujrathi S., Trapp R.G., Sweiss N.J., et al. Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B Cells) in combination with methotrexate in moderate-severe rheumatoid arthritis patients (Ph I/II ACTION Study). Arthritis Rheum 54 9 Suppl (2006) S66 [abstract]
32. Østergaard M., Wiell C., Sierakowski S., Wallace D., Kastberg H., Petersen J., and Dawes P.T. HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 54 9 Suppl (2006) S832 [abstract]
33. Burge D.J., Shu C., Martin R.W., Littlejohn T.W., Wallace D.J., Taborn J., Palmer W.R., and Kivitz A. TRU-015, a Small Modular ImmunoPharmaceutical (SMIP) drug candidate directed against CD20. Demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Rheum 54 9 Suppl (2006) S230 [abstract]
34. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol 17 (2005) 290-297
35. Steinfeld S.D., Tant L., Burmester G.R., Teoh N.K., Wegener W.A., Goldenberg D.M., and Pradier O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8 (2006) R129
36. Dorner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R74
37. Carnahan J., Stein R., Qu Z., Hess K., Cesano A., Hansen H.J., and Goldenberg D.M. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44 (2007) 1331-1341
38. Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C et al.: Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin's lymphoma. Blood 2007, March 20 [Epub ahead of print].
39. Tedder T.F., Baras A., and Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 28 (2006) 351-364
40. Sutherland A.P., Mackay F., and Mackay C.R. Targeting BAFF: immunomodulation for autoimmune diseases. Pharmacol Ther 112 (2006) 774-786
41. Dillon S.R., Gross J.A., Ansell S.M., and Novak A.J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5 (2006) 235-246
42. Sakurai D., Hase H., Kanno Y., Kojima H., Okumura K., and Kobata T. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 109 (2007) 2961-2967
43. Roschke V., Sosnovtseva S., Ward C.D., Hong J.S., Smith R., Albert V., Stohl W., Baker K.P., Ullrich S., Nardelli B., et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169 (2002) 4314-4321
44. Do R.K., Hatada E., Lee H., Tourigny M.R., Hilbert D., and Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192 (2000) 953-964
45. Ohata J., Zvaifler N.J., Nishio M., Boyle D.L., Kalled S.L., Carson D.A., and Kipps T.J. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 174 (2005) 864-870
46. Vallerskog T., Heimburger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., and Malmstrom V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8 (2006) R167
47. Halpern W.G., Lappin P., Zanardi T., Cai W., Corcoran M., Zhong J., and Baker K.P. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 91 (2006) 586-599
48. Furie R., Lisse J., Merrill J.T., Petri M., Ginzler E., Aranow C., Weinstein A., Strand V., Weisman M.H., Diskin K., et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS]) improves or stabilizes SLE activity in a multicenter phase 2 trial. Arthritis Rheum 54 9 Suppl (2006) S258 [abstract]
49. Fleischmann R., Wei N., Shaw M., Birbara C., Anand B., Gujrathi S., Hendricks R., Rao T., Ren S., Weingart M., et al. BR3-Fc Phase I Study: safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis. Arthritis Rheum 54 9 Suppl (2006) S229 [abstract]
50. Gommerman J.L., and Browning J.L. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3 (2003) 642-655
51. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
52. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., Emery P., Raemen F., Petersen J., Smolen J., et al. CHARISMA Study Group: double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
53. Sanz I., and Anolik J. Reconstitution of the adult B cell repertoire after treatment with rituximab. Arthritis Res Ther 7 (2005) 175-176
54. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54 (2006) 2377-2386
55. Lanzavecchia A., Bernasconi N., Traggiai E., Ruprecht C.R., Corti D., and Sallusto F. Understanding and making use of human memory B cells. Immunol Rev 211 (2006) 303-309